Kymab
Discovers and develops human antibody therapeutics.
Launch date
Employees
Market cap
-
Enterprise valuation
€1.0b (Public information from Jan 2021)
Company register number 07027523
Babraham England (HQ)
Financials
Estimates*
| EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|
| Revenues | 2.6m | 2.9m | 5.6m | 6.7m | 10.4m | 18.3m | 8.9m |
| % growth | 139 % | 12 % | 92 % | 19 % | 56 % | 76 % | (51 %) |
| EBITDA | (15.5m) | (27.9m) | (30.0m) | (50.0m) | (50.0m) | (40.0m) | (46.5m) |
| % EBITDA margin | (596 %) | (955 %) | (536 %) | (750 %) | (481 %) | (219 %) | (522 %) |
| Profit | (16.0m) | (26.2m) | (29.2m) | (47.9m) | (35.3m) | (35.3m) | (15.2m) |
| % profit margin | (613 %) | (900 %) | (522 %) | (719 %) | (339 %) | (193 %) | (171 %) |
| R&D budget | - | 26.0m | 26.0m | 2.0m | 5.0m | 10.0m | - |
| R&D % of revenue | - | 892 % | 465 % | 30 % | 48 % | 55 % | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
$30.4m | Series A | ||
$40.0m | Series B | ||
$50.0m | Series B | ||
$100m | Series C | ||
$9.0m | Grant | ||
$1.1b Valuation: $1.1b 54.7x EV/LTM Revenues -25.0x EV/LTM EBITDA | Acquisition | ||
| Total Funding | €209m | ||
Related Content
Recent News about Kymab
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.